Abstract
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that developed after a second mRNA-based SARS-CoV-2 vaccination.
Keywords: COVID-19; Japan; SARS-CoV-2; coronavirus disease; coronaviruses; immune checkpoint inhibitor; mRNA vaccine; nivolumab; respiratory infections; second SARS-CoV-2 vaccination; severe acute respiratory syndrome coronavirus 2; type 1 diabetes mellitus; vaccines; virus; zoonoses.
All Keywords
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, respiratory infections, zoonoses, SARS-CoV-2, Coronaviruses, Vaccines, mRNA vaccine, virus, Immune checkpoint inhibitor, Japan, Type 1 diabetes mellitus, nivolumab, second SARS-CoV-2 vaccination, 【초록키워드】 zoonoses, coronavirus, Diabetes Mellitus, immune, adverse events, mRNA, Patient, incidence, SARS-CoV-2 vaccination, acute respiratory syndrome, diabete, mRNA-based, 【제목키워드】 second, Type,
【저자키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, respiratory infections, zoonoses, SARS-CoV-2, Coronaviruses, Vaccines, mRNA vaccine, virus, Immune checkpoint inhibitor, Japan, Type 1 diabetes mellitus, nivolumab, second SARS-CoV-2 vaccination, 【초록키워드】 zoonoses, coronavirus, Diabetes Mellitus, immune, adverse events, mRNA, Patient, incidence, SARS-CoV-2 vaccination, acute respiratory syndrome, diabete, mRNA-based, 【제목키워드】 second, Type,
{{{ 추상적인 }}}
최근 니볼루맙과 같은 면역관문억제제의 사용이 증가하면서 제1형 당뇨병을 비롯한 면역관련 이상반응의 발생이 심각한 문제가 되고 있다. 우리는 두 번째 mRNA 기반 SARS-CoV-2 백신 접종 후 발병한 면역 관문 억제제-관련 1형 당뇨병이 있는 환자를 보고합니다.
{{ 키워드: }} 코로나19; 일본; 사스 코로나바이러스 2; 코로나바이러스 질환; 코로나바이러스; 면역 체크포인트 억제제; mRNA 백신; 니볼루맙; 호흡기 감염; 두 번째 SARS-CoV-2 예방 접종; 중증 급성 호흡기 증후군 코로나바이러스 2; 제1형 당뇨병; 백신; 바이러스; 인수공통전염병